Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this investigational study is to determine the safety and tolerability of oral
suberoylanilide hydroxamic acid when administered in combination with standard doses of
pemetrexed and cisplatin for the treatment of advanced solid tumors.